As Covid-19 cases rise, U.S. health officials mull widening additional booster eligibility
WASHINGTON, May 18 (Reuters) - Health officials are considering extending the eligibility for a second Covid-19 vaccine booster dose to people under 50 amid a steady rise in cases, with the United States seeing a threefold increase over the past month.
The U.S. Food and Drug Administration had in late March authorized a second booster dose of the Moderna MRNA.O and Pfizer PFE.N/BioNTech SE 22UAy.DE vaccines for people aged 50 and older, citing data showing waning immunity and the risks posed by Omicron variants of the virus.
“With regard to a fourth dose for those under the age of 50, that is going to require action from the FDA, and we’re in conversations there,” U.S. Centers for Disease Control and Prevention Director Rochelle Walenksy said on Wednesday.
Cases have steadily risen over the past five weeks, Walensky said at a White House briefing, with the the current seven-day average of daily cases rising 26% from the previous week to 94,000 cases per day and up threefold over the last month. The seven-day average for hospitalizations was up 19% to about 3,000 per day and the average for deaths was 275 per day, she said.
“We of course must remember that each person lost to Covid-19 is a tragedy and that nearly 300 deaths a day is still far too many,” said Walensky.
By Ahmed Aboulenein and Jeff Mason
(Reporting by Ahmed Aboulenein and Jeff Mason; Additional reporting by Susan Heavey; Editing by Alison Williams)
"Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]"